BioCentury
ARTICLE | Clinical News

RG3039: Phase I data

April 30, 2012 7:00 AM UTC

A blinded, U.S. Phase I trial in 32 healthy volunteers showed that single ascending-doses of RG3039 were well tolerated with no serious adverse events reported. Repligen also said there was evidence that RG3039 led to dose-related inhibition of DCPS of up to 90%. Data were presented at the American Academy of Neurology meeting in New Orleans. The trial was partially funded by the Muscular Dystrophy Association. ...